Mirati Therapeutics initiated with an Outperform at Credit Suisse. Credit Suisse analyst Michael Morabito started coverage of Mirati Therapeutics with an Outperform rating and $85 price target. The analyst believes Mirati holds “several very promising” assets, such as its MRTX849, a highly specific inhibitor of the G12C-mutated KRAS protein, mutations in which are common in multiple cancers. With only one competing drug in clinical development, the competitive landscape is not substantial, he notes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.